Editas Medicine, Inc. (NASDAQ:EDIT) insider Katrine Bosley sold 8,333 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $23.64, for a total transaction of $196,992.12. Following the completion of the sale, the insider now owns 1,393,322 shares of the company’s stock, valued at approximately $32,938,132.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Katrine Bosley also recently made the following trade(s):
- On Monday, October 2nd, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The shares were sold at an average price of $24.78, for a total value of $206,491.74.
- On Friday, September 1st, Katrine Bosley sold 10,000 shares of Editas Medicine stock. The shares were sold at an average price of $20.42, for a total transaction of $204,200.00.
- On Tuesday, September 5th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.33, for a total transaction of $338,819.78.
- On Friday, August 11th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.02, for a total transaction of $333,653.32.
Shares of Editas Medicine, Inc. (NASDAQ:EDIT) opened at $24.68 on Tuesday. Editas Medicine, Inc. has a 52 week low of $13.12 and a 52 week high of $29.20. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 0.19.
Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.04). The company had revenue of $6.28 million during the quarter, compared to the consensus estimate of $2.66 million. Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. Editas Medicine’s quarterly revenue was up 553.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.59) EPS. equities research analysts expect that Editas Medicine, Inc. will post -2.86 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.truebluetribune.com/2017/11/14/katrine-bosley-sells-8333-shares-of-editas-medicine-inc-edit-stock.html.
Several large investors have recently bought and sold shares of EDIT. Bank of New York Mellon Corp lifted its position in shares of Editas Medicine by 53.3% in the 1st quarter. Bank of New York Mellon Corp now owns 63,490 shares of the company’s stock worth $1,418,000 after purchasing an additional 22,061 shares during the period. Swiss National Bank lifted its position in shares of Editas Medicine by 33.2% in the 1st quarter. Swiss National Bank now owns 40,100 shares of the company’s stock worth $895,000 after purchasing an additional 10,000 shares during the period. Thrivent Financial For Lutherans bought a new stake in Editas Medicine during the 1st quarter valued at about $1,137,000. Vanguard Group Inc. grew its stake in shares of Editas Medicine by 47.0% in the first quarter. Vanguard Group Inc. now owns 1,935,173 shares of the company’s stock worth $43,193,000 after acquiring an additional 618,789 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Editas Medicine by 4.7% in the first quarter. Geode Capital Management LLC now owns 119,376 shares of the company’s stock worth $2,664,000 after acquiring an additional 5,397 shares during the period. 67.17% of the stock is owned by hedge funds and other institutional investors.
EDIT has been the topic of a number of research reports. Zacks Investment Research cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $28.00 target price (up previously from $27.00) on shares of Editas Medicine in a research note on Friday, October 6th. ValuEngine upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Cann reiterated a “hold” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Finally, Cowen and Company restated a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Editas Medicine presently has a consensus rating of “Hold” and an average price target of $26.73.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.